Monthly Archives: March 2022
Systemic Therapy for Hepatocellular Carcinoma Clinical Decision Support Tool
AGA Guideline, Gastro: https://www.gastrojournal.org/article/S0016-5085(21)04172-X/fulltext Continue reading
GI Rapid Reel: Potential Effects of Lowering Colorectal Cancer Screening Age
AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC), the most common primary liver cancer, remains a deadly cancer, with an incidence that has tripled in the United States since 1980. In recent years, new systemic therapies for HCC have been approved and a critical assessm… Continue reading
AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma
Liver cancer is the seventh most common cancer worldwide, and the sixth leading cause of cancer-related mortality in the United States.1,2 Hepatocellular carcinoma (HCC), the most common histologic type of liver cancer, occurs most commonly in patients… Continue reading
Dysplastic recurrence after successful treatment for early Barrett’s neoplasia: development and validation of a prediction model
The combination of endoscopic resection and radiofrequency ablation is the treatment of choice for eradication of Barrett’s esophagus (BE) with dysplasia and/or early BE cancer. Currently, there are no evidence-based recommendations on how to survey pa… Continue reading
Impact of Artificial Intelligence on Miss Rate of Colorectal Neoplasia
Artificial Intelligence may detect colorectal polyps that have been missed due to perceptual pitfalls. By reducing such miss rate, Artificial Intelligence may increase the detection of colorectal neoplasia leading to a higher degree of Colorectal Cance… Continue reading
Regulation of PGC1α downstream of the insulin signaling pathway plays a role in the hepatic proteotoxicity of mutant α1-antitrypsin deficiency variant Z
Insulin signaling is known to regulate essential proteostasis mechanisms. Continue reading